The author argues CVRx trades near $2.80 while activist holder Jorey Chernett, owning over 5.5%, has demanded the Board begin a strategic alternatives review prioritizing a sale. The catalyst is an announcement that CVRx has hired an independent financial advisor or investment bank to evaluate strategic alternatives, which the author believes could double the stock as investors speculate on MedTech buyers for Barostim. The main risk implied is that no such announcement or sale materializes.